Robeco Institutional Asset Management B.V. Sells 108,349 Shares of Gilead Sciences, Inc. $GILD

Key Points

• Robeco Institutional Asset Management B.V. reduced its Gilead stake by 108,349 shares (a 2.8% cut), leaving it with 3,693,602 shares — about 0.30% of Gilead and roughly 0.6% of Robeco’s portfolio (its 22nd largest holding).
• Gilead slightly beat quarterly estimates with EPS of $1.86 versus $1.83 and revenue of $7.93B (up 4.7% YoY), and set FY2026 guidance of 8.45–8.85 EPS versus sell‑side consensus near 7.95.
• The company is accelerating its oncology push — agreeing to acquire Tubulis for up to $5 billion and licensing KT‑200 (triggering a $45M milestone) — while also raising its quarterly dividend to $0.82 ($3.28 annual, ~2.4% yield).

Robeco Institutional Asset Management B.V. reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,693,602 shares of the biopharmaceutical company's stock after selling 108,349 shares during the quarter. Gilead Sciences accounts for approximately 0.6% of Robeco Institutional Asset Management B.V.'s investment portfolio, making the stock its 22nd biggest holding. Robeco Institutional Asset Management B.V. owned approximately 0.30% of Gilead Sciences worth $453,353,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. Brighton Jones LLC raised its position in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock worth $1,326,000 after acquiring an additional 2,450 shares in the last quarter. Bison Wealth LLC bought a new stake in Gilead Sciences during the fourth quarter worth $215,000. Sivia Capital Partners LLC raised its position in Gilead Sciences by 16.8% during the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company's stock worth $464,000 after acquiring an additional 602 shares in the last quarter. Ieq Capital LLC raised its position in Gilead Sciences by 12.0% during the second quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company's stock worth $13,160,000 after acquiring an additional 12,705 shares in the last quarter. Finally, Diversify Advisory Services LLC raised its position in Gilead Sciences by 18.6% during the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company's stock worth $516,000 after acquiring an additional 674 shares in the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Trading Down 2.2%

GILD stock opened at $139.03 on Friday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55. The company's 50-day simple moving average is $145.13 and its 200 day simple moving average is $130.47. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The company has a market capitalization of $172.56 billion, a PE ratio of 20.54, a price-to-earnings-growth ratio of 1.85 and a beta of 0.39.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the prior year, the company posted $1.90 earnings per share. Gilead Sciences's revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 30th. Investors of record on Friday, March 13th were paid a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.4%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.79. The ex-dividend date was Friday, March 13th. Gilead Sciences's dividend payout ratio is currently 48.45%.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to acquire Tubulis for up to $5 billion to expand its ADC oncology pipeline — a strategic bolt-on that supports Gilead’s shift into oncology and could drive longer‑term revenue growth. Gilead Sciences (GILD) to Acquire Tubulis for $5B to Strengthen Oncology Pipeline
• Positive Sentiment: Gilead exercised its option to license KT‑200 from Kymera, triggering a $45M milestone payment to Kymera and adding a first‑in‑class oral CDK2 degrader to its discovery-to-clinic pipeline — a validation of Gilead’s external innovation strategy. KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200
• Positive Sentiment: Research partners and collaborations: expanded RWE and oncology R&D tie-ups (Tempus, Cartography) reinforce Gilead’s push to accelerate translational work and de‑risk discovery-stage assets. Tempus Announces Strategic Collaboration with Gilead
• Positive Sentiment: Sell-side lifts and bullish notes: Morgan Stanley raised its price target to $175 with an overweight rating (largest upside among today’s notes), and Truist also nudged up its target — these analyst actions can support buying interest. Price target raise at Morgan Stanley (Benzinga)
• Neutral Sentiment: Short‑interest data for April is effectively meaningless/zero in the report (shows 0 shares / NaN change), so it doesn’t provide directional insight into current positioning.
• Negative Sentiment: Cantor Fitzgerald cut its price target sharply to $115 (while oddly maintaining an overweight rating), introducing downside headline risk and signaling divergent analyst views on valuation. Cantor Fitzgerald Adjusts Price Target on Gilead Sciences
• Negative Sentiment: The AIDS Healthcare Foundation publicly criticized Gilead over its role in a Florida drugs situation — reputational and regulatory scrutiny can pressure sentiment and potentially elevate legal/regulatory risk. AHF Slams Gilead for Role in Florida AIDS Drug Crisis

Insider Buying and Selling at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the chief financial officer directly owned 179,191 shares in the company, valued at approximately $25,844,717.93. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the completion of the transaction, the insider owned 120,288 shares in the company, valued at $18,577,278.72. This trade represents a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 299,280 shares of company stock valued at $42,820,550. 0.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on GILD. Rothschild & Co Redburn upped their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a "buy" rating in a research report on Tuesday, February 17th. Mizuho upped their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the company an "outperform" rating in a report on Wednesday, February 18th. Needham & Company LLC reiterated a "buy" rating and issued a $170.00 price objective on shares of Gilead Sciences in a report on Monday, February 23rd. Barclays assumed coverage on shares of Gilead Sciences in a report on Friday, February 20th. They issued an "equal weight" rating and a $155.00 price objective on the stock. Finally, Sanford C. Bernstein reiterated an "outperform" rating and issued a $160.00 price objective on shares of Gilead Sciences in a report on Wednesday, February 11th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $156.42.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.